Extracellular non-adenine based purines are neuroprotective. Preliminary studies indicate that administration of the synthetic purine 4-[[3-(1,6 dihydro-6-oxo-9-purine-9-yl)-I-oxypropyl] amino] benzoic acid (AIT-082, leteprinim potassium) to rats immediately after acute spinal cord injury (SCI), improves functional outcome. The effects of potential new agents are often compared to methylprednisolone (MPSS). We evaluated the effects of AIT-082 and MPSS, separately and in combination, on the functional and morphological outcome of acute SCI in adult rats. After standardized TH-l2 spinal cord compression rats were given intraperitoneally one of the following: vehicle (saline); MPSS (30 mg/kg or 60 mglkg body weight, first dose 15 min after crush); AIT-082 (60 mg/kg body weight daily, first dose 15 min after crush); or AIT-082 plus MPSS. After 1, 3, or 21 days, the rats were perfused for histological analysis. AIT-082 administrations significantly reduced locomotor impairment from 1-21 days post-operatively. At 1 and 3 days post injury, AIT-082-treatment reduced tissue swelling, tissue loss and astrogliosis at the injured cords but did not alter the extent of hemorrhage and the number of macrophages and/or microglia. MPSS reduced hemorrhage and the number of macrophages and/or microglia, but did not alter astrogliosis. At 21 days, either AIT -082 or MPSS administration improved function and morphology similarly (less tissue loss and astrogliosis). In contrast, administration of AIT-082 and MPSS together abolished the beneficial effects observed when either drug was given individually. These results suggest that MPSS and AIT-082 may exert their beneficial effects through different and potentially antagonistic pathways.
Many reports have indicated that secondary tissue damage occurs in traumatized spinal cords, which causes neurological deficit (1-3). Certain treatments have been shown to reduce tissue damage and improve neurological recovery when administered shortly after spinal cord injury (SCI) (4) . For example, many pharmacological agents have been reported to reduce secondary injury and to be neuroprotective in a variety of animal models of SCI. These include methylprednisolone (5) (6) (7) (8) ; non-steroidal anti-inflammatory agents (2, 9) ; antiexcitotoxicity agents (10) (11) (12) ; anti-apoptotic drugs (11); free radical scavengers (11) and other compounds with uncertain mechanisms of action. Together these studies validate the concept of a treatable secondary component to acute SCI.
Clinically, high-dose methylprednisolone sodium succinate (MPSS, a synthetic corticosteroid) was the first treatment shown to improve recovery in human SCI, and it remains the only form of management in a Phase 3 trial to have demonstrated efficacy in treating this injury (13, 14) . Therefore, MPSS has become the' standard' treatment against which the efficacy of all new potential therapies are tested (2, 15) .
Neotrofin, a synthetic hypoxanthine derivative, (AIT-082 4-[[3-(1,6 dihydro-6-oxo-9-purin-9-y1)-l-oxypropy1] amino] benzoic acid, leteprinim potassium), in animal and cell culture studies has been shown to be both neuroprotective and to stimulate nerve regeneration. For example, we have shown that it stimulates neurite outgrowth from PC 12 cells in tissue culture through a mechanism involving heme oxygenase, carbon monoxide and increase in intracellular guanosine 3',5' cyclic monophosphate (cGMP) (16) More recently, Wang and his colleagues (17) reported that high dose AIT -082 has neuroprotective effects through increasing heme oxygenase-l (HO-I) selectively in neurons. AIT-082 attenuates glutamate toxicity in cultured hippocampal neurons (18) ; protects againstNMDA toxicity in neuronal cultures from the hippocampus and cerebral cortex (19) and prevents excitotoxic death of hippocampal neurons following kainate-induced status epilepticus in rats (20) . In addition, given either orally or intraperitoneally, AIT -082 has no appreciable side effects and crosses the blood-brain-barrier (21) .
Our preliminary studies indicate that AIT-082 improved locomotor function when given to rats after acute SCI (22) . In the present study we assessed the effects of AIT -082 on tissue damage and functional recovery after spinal cord crush injury, comparing these effects with those resulting from MPSS alone, as well as those with AIT -082 in combination with MPSS.
MATERIALS AND METHODS
All experiments were performed in compliance with the requirements of the Animals for Research Act of Ontario, Canada and the Guidelines of the Canadian Council on Animal Care (CCAC), and had been approved by the Animal Research Ethics Board (AREB) of McMaster University.
Animals
Adult female Wistar rats (280-300g body weight, Charles River) were maintained in a temperaturecontrolled vivarium on a 12:12 h light:dark cycle with food and tap water freely available. Rats were handled daily for 2 weeks before surgery and trained in open field walking and inclined climbing tasks.
Surgical procedures
Rats were anaesthetized with isoflurane (3-5%): 02 (lLlmin). Buprenorphine (0.03 mg/kg body weight, subcutaneously) was given before surgery for pain relief. We did a TIl-TI2 laminectomy to expose the spinal cord and crushed the cord with modified coverslip forceps (23, 24) . The forceps were closed slowly (over 2 seconds), compressing a 3.5 mm length of the spinal cord to a thickness of 1.4 mm for 15 seconds. Muscles and fat pad over the lesion were sutured and the skin was clipped with stainless steel clips to close the wound. Postoperatively, the rats were kept quiet and warm.
This model of spinal cord trauma is based on compression of the cord to a set thickness for 15 seconds (46) , as an alternative to compression or contusion with a set force of displacement for a short time. The model is technically simple, reliable, and has been used by other laboratories (23) (24) (25) (26) . Crushing the spinal cord in the way of short compression time at low speed does mimic a common human condition of transient severe compression of the spinal cord. In our experience, about 91 % of rats (n= 102, unpublished data) with this degree of crush recover and stabilize within the range of9.0 to 10.8 on the locomotor function scale at 21 days after injury. Our present results indicate that this procedure not only leads to very consistent histological changes and behavioral deficits, but also demonstrates that these effects can be significantly altered by pharmacological therapy.
Drug preparation and administration
Each rat was assigned sequentially to one of four treatment groups. Each group received one of the following treatments: vehicle (saline), AIT -082, MPSS or AIT-082 plus MPSS. AIT-082 (NeoTherapeutics Inc., Irvine, CA) was dissolved in normal saline (0.9% sodium chloride) at physiological pH (7.2-7.4) (50 mgt ml) and injected intraperitoneally (60 mg/kg body weight, daily i.p, first dose at 15 minutes after crush). Methylprednisolone sodium succinate was prepared in saline (l00 mg/ml) and given by i.p. injection (60 mgt kg, 15 min after crush, then 30 mg/kg at 2, 4 and 6 h after crush). Animals in the AIT -082 plus MPSS group received AIT-082 60 mg/kg plus MPSS 60 mg/kg at 15 min; MPSS 30 mg/kg at 2, 4 and 6 h after crush and AIT-082 60 mg/kg daily on subsequent days. Control rats received equivalent volumes of saline by i.p. injection instead of the drug-containing solutions. All treatments were coded, so that the investigators responsible for evaluating and analyzing the outcomes did not know which rat received which treatment.
Behavioral assessment
All rats were handled daily for 2 weeks preoperatively to acclimatize them to the experimental procedures. On days I, 2, 3, 7, 10, 14 and 21 post surgery (surgery day was on day 0), we evaluated the locomotor behavior and segmental reflexes ofthe rats. Four tests were used: an open field walking task (27, 28) , hind limb placement (24) , foot orienting response (23, 24, 29) and an inclined plane test (30, 31) .
An open field walking test (OFWT) was conducted once a day before surgery, and on the indicated days after surgery. Cagemates (two animals) were placed in the center of an open field, formed by a child's circular plastic swimming pool. They were observed for 5 min periods, and scored for general locomotor ability using the BBB (Basso, Beattie, and Bresnahan) scale (27, 28) . Rats were rated on a scale of 0 to 21, 0 being no function and 21 being normal.
Hind limb placing response (HLPR) and foot orienting response (FOR) were each scored on a scale of 0 to 2, 0 indicating no function and 2 indicating full function (29) . Half-scores were assigned if the behavioral response appeared intermediate. Hind limbs were scored separately for each measure. To assess HLPR, we grasped the hind foot between the thumb and forefinger, pulled backwards, and then released the foot. The placement of the foot on the table surface was then scored (24) . The FOR followed Gruner's (24) protocol modified from the previous descriptions of this reflex (29) .
The inclined plane test (lPT) measured the ability of the rats to maintain their position for 5 s on an inclined plane, covered by a rubber mat containing horizontal ridges (I mm deep, spaced 3 mm apart). The rats were observed as the angle of the surface was increased from 5' to 90' at 5' intervals. The angle at which the rat could no longer stay in position was the outcome measure.
Histological analysis Tissue preparation
Between 7 and 9 rats in each experimental group were killed on day I and on day 3 after surgery. Between II and 12 rats per experimental group were killed on day 21. The rats were deeply anesthetized with sodium pentobarbital (50-60 mg/kg body weight, i.p.) and perfused transcardially; first with 100 ml 0.05M phosphate buffered saline (PBS) containing 0.1 % heparin, followed by 300-500 ml of 4% paraformaldehyde (PFA). The T9 to LI segments of the spinal cords were removed and incubated in the same fixative solution for 2 h at room temperature and then cryo-protected in 30% sucrose PBS solution. A segment of each cord, extending from 5 mm rostral to 5 mm caudal to the lesion site was embedded in medium (Tissue-Tek®O.C.T. compound, Sakura Finetek U.S .A., Inc., Torrrance, CA 90504 U.S.A.). Serial sections, both cross and longitudinal, were cut at 20 urn intervals on a cryostat and mounted onto slides (ColorFrost/ Plus; Fisher, Pittsburgh, PA) for staining. Some crosssections were stained with hematoxylin and eosin (H&E) and for immunohistochemical analysis (Glial Fibrillary Acidic Protein [GFAP], and ED-I, an antibody against macrophages and microglia-positive cells) using the antibodies described in the section below. Longitudinal sections were cut for luxol fast blue staining, a lipophilic dye used commonly to stain myelin (32) .
Immunochemistry
To reduce endogenous peroxidase activity, the cryostat sections were thawed, air dried and then incubated in hydrogen peroxide (0.5%) and PBS for 30 min, before being rinsed three times over a 10 min period in PBS. Sections were then incubated in I % sodium borohydride for 15 min. After thorough washing with PBS, sections were treated with 5% normal goat serum in PBS containing 0.3% Triton X-IOO at room temperature for 30 minutes. Overnight incubation with primary antibody was performed in humidified boxes at 4°C. Reactive astrocytes (astrogliosis) were determined with a rabbit poly clonal antibody against GFAP (Zymed" Lab-SA System Kit, dilution I :600) and macrophages and/or microglia, with a mouse monoclonal antibody against ED-I (MCA 341 R, 1:500; Serotec, Hornby ON, Canada). The primary antibodies were diluted in PBS/5% normal goat serum with 0.3% Triton X-IOO. After PBS rinsing, sections were then incubated with Elite avidin-biotinylated-complex (ABC; Vector Laboratories, Burlingame, CA) for I hr, followed by 3,3'-diaminobenzidine (DAB) substrate (Vector Laboratories) for 5-1 0 min. Sections were then dehydrated with alcohol, cleared with xylene. Coverslips were mounted with Histomount. Sections were examined under a light microscope.
Tissue loss
Five longitudinal sections were taken from each cord and stained with luxol fast blue. The sections, which contained the greatest lesion area, as well as the adjacent 2 dorsal and 2 ventral sections taken at 100/lill intervals, were selected to measure the size of spinal cord lesion. Digital images of the sections were obtained using a Zeiss microscope. The average area of the cystic cavity was determined using a Bioquant BQ-TCW98 image analysis program by an investigator who was blind to group assignment.
Measurement of gliosis
To quantify GFAP-positive cells, we assessed 5-7 cross-sections from each animal at the lesion site (every third section, 100 urnapart). We counted the number of GFAP-labeled cells with the Bioquant BQ-TCW98 image program. Each section had been stained immunocytochemically for GFAP. Reactive astrocytes were characterized by their intense GFAP immunoreactivity. Glia that had an intensive staining that was equal to or more than a set threshold (the setting determined in the untreated controls that outlined all the GFAP-positive cells) were counted as GFAPreactive astrocytes. Data are expressed as the number of immunostained cells per section (mean±SEM).
Statistical analysis
Statistical analyses were performed on a Macintosh computer using a commercial program GB-Stat ppc 6.5.2 (New England Software, Inc.). The statistical significance of behavioral scores was estimated by Kruskal-Wallis non-parametric analysis of variance (ANDYA) followed by Mann-Whitney U test. Correlation between the behavioral tests and tissue loss was analyzed by linear regression.
RESULTS

Behavioral outcome
Control animals subjected to laminectomy alone had no observable behavioral deficits after injury. They all maintained their pre-operative scores perfectly in the four different tests, i.e. 21 motor score in the OFWT, 2 in FOR and HLPR and 90 0 grade in IPT. Over the course of 21 days, saline-treated SCI rats recovered occasional weight supported plantar steps, with no fore-hind limb coordination, reflecting a mean BBB locomotor score of 10.04±0.73 by 21 days after SCI (Fig. I) . In contrast, the AIT-082treated rats recovered to aBBB score of 13.09±0.7. They exhibited frequent to consistent weightsupported plantar steps with frequent fore-hind limb coordination. The MPSS treated rats also recovered consistent weight-supported plantar steps with occasional to frequent fore-hind limb coordination (12.06±0.68). Thus, rats treated either with AIT -082 or MPSS recovered to a similar extent, and had significantly better neurological function, than rats that received saline treatment (p<0.05).
Saline-treated SCI rats had a FOR score of 0.94±0.1O (Fig. 2) . These rats extended their hind legs laterally with toe spread but turned their feet outward. When these rats were lowered, they did not orient their feet toward the ground. In contrast, the AIT -082 treated rats recovered to a score of 1.46±0.1 O. When held by the tail above the ground, the hind limbs were spread laterally although at times the hind limbs were spread further apart or closer together than normal. The MPSS treated rats obtained a FOR score of 1.37±0.15 and this was similar to the AIT -082 treated rats (Fig. 2) .
Rats always placed an extended hind limb briskly beneath the body in a propioceptive placing response. Injured rats placed their hind limb either less normally, or partially, or unreliably, or not all, depending on the time since the injury and the treatment. At 21 days after injury, saline-treated rats attained a 0.99±0.12 (Fig. 3 ) HLPR score characterized by little or no attempt to place their foot, or leaving the foot extended with its dorsal surface down. In contrast, AIT -082-treated rats reached a score of 1.67±0.06 (Fig. 3 ) characterized by impaired placement, but close to normal with quick retraction of the limb and placement of the foot with its plantar surface down, but with the toes curled. MPSS-treated rats reached an HLPR score of 1.30±0.13 (Fig. 3 ) indicated by impaired foot placement with slow retraction and with dragging of dorsal surface/knuckles before placing the foot, and placing the foot with toe curl.
Uninjured rats maintained their position on the inclined plane up to an angle of 90°. After injury, saline-treated SCI rats lost their ability to ....
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maintain their po srtr on be yond 70°, before recovering slightly to 73°± 1.75 by 21 days after injury. In contrast, AIT -082 treated rat s were able to maintain their positi on to a mean incline of 82°± 1.24, while MPSS treated rats were able to maintain an incline of 83o± 1.02 (Fig. 4) .
Interestingly, comb ining AIT-08 2 and MPSS abolished the beneficial effects observed when either drug was admini stered alone. Behavioral test scores did not differ sig nifi cantly bet ween saline-treated animal s, and those, which recei ved a combination of AIT-082 plu s MPSS (Figs. 1, 2  and 3 ). As with saline-treated rats, those rats tre ated with AIT-082 plu s MPSS recovered occasional weight-supported plantar steps, with 
. Effec t ofA fT-D82treatm ent on the developm ent ofreac tive as trogliosis 3 days (a) -(d) and 21 days (e) -(h)follow ing a cru sh lesion to rat spinal co rd. Three days afte r injury. spinal cord sections f rom the lesion sites were stained f or GFAP-immunoreacti vity. (a): Vehicle cont rol. Nume rous reactive astrocytes are characterized by their intense GFAP-immunoreactivity and hyp ertrophic cell bodies . (b): A fT-D82-treated. Both the intensity of GFAP-IR and the number of reactive astrocytes are remarkably reduced as compared to the vehicle-treated contro l. (c, d): Lesion site f rom MPSS (c) and AfT-D82 plus MPSS treated groups (d). In both (c) and (d) GFAP-immunoreactivity is similar to that in the vehicle control gro up. Bar= 6DJ1mfor all. (e): The lesion site from vehicle controls contains num erou s reactive astrocytes characte rized by intense GFAP-immunoreac tivity and hyp ertrophic cell bodies. In an imal s treat ed with eit her A fT-D82 if) or MPSS (g). the intensity of GFAP -immu noreactivity and the number ofreactive astrocytes are remarkably reduced as compared to the vehicle-tre ated control. In contras t. in an imal s treat ed with A IT-D82+MPSS (h) there are, as in co rds from vehicle -treated animals, num erou s reacti ve astrocytes , cha racterized by intense GFAP -immunoreactivity and hyp ertrophic cell bodies. Bar= 5DJ1m f or all .
no fore-hind limb coordination. At 2 1 days, these rats had a BBB score of 9.86±0 .83/21 (Fig. 1) , a FOR score of 0.92±0.1412 (Fig. 2) , and an HLPR score at 0.89±0.1312 ( Fig. 3) and an incline plane score of 75°±1.42 (Fig. 4) .
Histological analysi s
The major difference in neurological function between groups of animals tre ated with AIT -082 or MPSS and those tre ated with either saline or a combination of AIT -08 2 and MPSS was observed with in the first 24 hours after injury (Fig. 1,2, and  3) . Thi s indicated that the AIT-082, like MPSS, might exert an early neuroprotective effect. We therefore compared the histologic al appearance of the injured spinal cords from the various treated groups at 24 and 72 hours, and 21 days after injury.
Histological examination of H&E stained sections from untreated control animals showed gross disruption of spinal cord tissue architecture with edema and hemorrhage at the injury site. At 24 hours, MPSS-treated spinal cords showed less edema, less hemorrhages and less structural disruption at the injury site compared to those from saline-treated rats (Fig. 5 ). Spinal sections from AIT-082-treated rats also had less edema and disruption of structure, but no change in the extent of hemorrhage (Fig. 5 ). Sections from animals treated with the combination of AIT -082 plus MPSS did not differ appreciably from control animals. The general histological appearance of the spinal cords did not differ between day one and three.
Tissue loss
At 21 days , all the injured cords stained with luxol fast blue had obvious necrosis at the injury site . Measurements of the mean cystic cavity size (6 rats per group, 5-7 sections per rat) revealed a significant reduction ofthe cavity size in AIT -082 or MPSS-treated rats compared to saline-treated controls (Fig.6e; p<0 .05). However, cavity size of . .
AIT -082 plus MPSS-treated rats did not differ significantly from saline controls (Fig.6e) . The necrotic areas of spinal cords from rats treated with AIT -082 or MPSS correlated with BBB scores (r=-0.56; p<O.O I and r=-0.48; p<0.05, respectively).
Gliosis
In the present study, reacti ve astrocytes in the injured spinal cord exhibited astrocytic hypertrophy (Fig. 7a , Tab. I). We counted the number of these reactive astrocytes at 1 and 3 days in 4-5 animals from each group and at 21 days in 5-7 animals from each group. One day after injury none of the treatments altered the number of reacti ve astrocytes. However, at 3 days AIT-082-treated rats had significantly fewer reactive astrocytes than saline controls (Fig. 7b ). Rats treated with either MPSS (Fig. 7c ) or AIT-082 plus MPSS (Fig. 7d ) had similar numbers of reactive astrocytes as saline controls at 1 and 3 days. However, by 21 days after injury either injured spinal cords from rats treated with MPSS or AIT-082 had significantly fewer reactive astrocytes than cords from control animals or those treated with AIT -082 plus MPSS ( Fig. 7e-7h , Tab. I).
To observe the changes in macrophages and/ or microglia, we used ED-l immunostaining, which stained both macrophages and/or microglia. ED-1-positive cells were observed at the injury site of spinal cords from all experimental groups at 1 day after injury (Fig. 8 ). Only MPSS treatment reduced the number of ED-l positive macrophages and/or microglia (Fig. 8 ). The number of ED-l positive cells at 3 days after injury was similar to that after 1day in the injured cords from the rats treated with AIT-082, or saline, or AIT-082 plus MPSS. These results indicate that high doses of methylprednisolone treatment suppress ED-l positive macrophages and/or microglia at the injury site.
DISCUSSION
Our study is a detailed report of multiple histological and neurological outcome measures when the spinal cords of rats are crushed and received various treatments. We have been able to correlate histological and behavioral changes under different experimental conditions. These data indicate that after spinal cord injury in rats, daily intraperitoneal injections of AIT -082 (60mg/kg) for 21 days significantly improved multiple measures of neurological function. These improvements were paralleled in histological studies by less tissue swelling, less cellular degeneration, less necrosis and less astrogliosis compared to control animals. Effects of AIT -082 on behaviour were similar to those produced by high dose MPSS. However, within the first 3 days of spinal injury the two drugs affected different cell types. MPSS reduced the numbers of macrophages and/or microglia at the injury site but had little or no effect on the extent of astroglia. In contrast, AIT-082 did not inhibit the accumulation of macrophages and/or microglia at this time period, but caused a decrease in the number of reactive astroglia. Interestingly, administration of AIT-082 and MPSS together in rapid succession abolished the beneficial effects observed when either compound was given individually.
The histological measurements correlated significantly with the BBB scores. Linearregression analysis showed an inverse correlation between the size of the necrotic area and the BBB scores. The correlation coefficient was close to 0.5.
Recovery of locomotion and limb placement depends on ascending and descending spinal cord tracts, including rubro-, reticulo-, vestibulo-, and raphe-spinal tracts (33) . The initial functional loss after spinal cord injury in rats may result from the interruption of descending serotonergic (34) , reticulospinal and other descending spinal tracts that facilitate segmental reflexes (24, 35) . Improved recovery of all four behavioral measures suggests that both AIT -082 and MPSS protect multiple ascending and descending spinal tracts.
Astrogliosis is a prominent reaction to traumatic spinal cord injury (36) (37) (38) (39) (40) . After injury, inflammatory responses rapidly induce marked astrocytic changes, referred to as reactive gliosis. Astrocytes, the major glial cells in the CNS, maintain the homeostatic microenvironment and are also immunocompetent cells playing an important role in immune regulation, acting as a source of chemokines, cytokines and adhesion molecules (41) . These are the immunological mediators. When stimulated by pro-inflammatory cytokines, activated astrocytes may produce several inflammatory meditors including interleukin (Il.)-I«, IL-I3, IL-6, lymphotoxin (LT -13), and tumor necrosis factor (TNFa) (42) , as well as IL-8, monocyte chemotactic protein-1 (MCP-1), granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophagecolony stimulating factor (GM-CSF) (41) . A principal stimulus for astrocyte proliferation is the release of cytokines such as interleukin (Il.)-113 (43) , tumor necrosis factor (TNFa; 43) and IL-6 (44, 45) from microglia. Therefore, reactive gliosis may result from an autoimmune reaction trigged by the injury. AIT-082 reduced both the extent of tissue damage after the standardized spinal cord injury and the amount oftissue swelling as well as concomitantly reducing astrogliosis. MPSS did not reduce astrogliosis. Studies have shown that MPSS inhibits the expressions of several cytokines (46, 47) .
The mechanisms by which AIT -082 protects the spinal cord are not clear. There are several possibilities that could be considered. First, very high doses of AIT-082 were given in these experiments. At the concentration achieved after i.p. injection of 60 mg/kg, AIT -082 may be acting through non-receptor mediated mechanisms, including acting as an antioxidant. Second, AIT-082 protects neurons against glutamate-induced excitotoxicity, (20, 48) , against kainate-induced neuronal injury in the hippocampus of rats (20) and against NMDA-induced lesions (48) . AIT-082 is not a glutamate receptor antagonist, nor does it interact directly with adenosine A,-receptors (Caciagli, personal communication). This indicates that its effects cannot be attributed to its influence on these pathways. Third, it has been proposed (48, 49 ) that AIT -082 may exert its neuroprotective effects by protecting astrocytes, which express adenosine A 1 -and metabotropic (mGluR) 11receptors. Finally, certain effects of AIT -082 may be mediated through a heme Oxygenase-l (HO-l) mechanism (16, 17) . HO-1 has been shown recently to be neuroprotective (50) .
MPSS is the only therapeutic agent used in the treatment of acute traumatic SCI in humans. This therapy is based on reported improvements in neurological recovery in humans and laboratory animals (7, 13, 14, 52, 51) and by its reduction in early pathophysiological events and macrophage infiltration (46, 53, 54) . Our current study adds to these reports by showing that MPSS reduced hemorrhage, tissue swelling, macrophage infiltration, microgliosis, and tissue cavitations in crushed spinal cords and by showing that the histological changes correlate with functional improvement (coefficient of correlation between tissue loss and OFWT score is -0.48).
The effects of MPSS on spinal cord injury may depend on the dose, the timing of treatment, the duration of treatment, and the spinal cord injury model used (55) . Although MPSS has been shown to reduce the expression of inflammatory cytokines, downregulate lipid peroxidation in the spinal cord and reduce the density of ED-I-positive macrophages or/and microglia at the first 2 days after contusion (46, 56) , significant functional recovery associated with these biochemical or histological changes was not observed.
The actions of MPSS in spinal cord injury may depend on mechanisms other than steroid receptor activation (8, 9, 52, 57) . Certainly the dose of MPSS used in these experiments is much higher then those required saturating steroid receptors. Our finding that MPSS reduced swelling, hemorrhage, and the number of macrophages, is consistent with protection of the vasculature and reduction of inflammation (58, 59) .
The neuroprotective effects ofMPSS and AIT-082 are antagonistic. Unlike MPSS, AIT-082 does not appear to have anti-inflammatory effects nor does it antagonize the anti-inflammatory effects of MPSS in carragenin-induced foot-paw inflammation (Crocker and Rathbone, unpublished observations). There are several possibilities to account for the fact that the two treatments, which have beneficial effects when used alone, lose their effectiveness when used in combination. First, AIT -082 increases cytokines and neurotrophin expression associated with inflammation and this expression is abolished by MPSS (46, 47) . Second, AIT -082 stimulates the release ofNGF, NT-3, and bFGF from astrocytes (49) and MPSS reduces either astrocyte (60) or oligodendrocyte precursor proliferation (61) . Therefore, MPSS may reduce the effects ofNGF, NT-3, and bFGF. Third, MPSS activates calcium currents in astrocytes (62) , which, in turn, may be the basis for their protective activity in SCI (9) . AIT -082 does not increase intracellular calcium concentrations, but does hyperpolarize cells, which may counteract the MPSS-induced increase in calcium levels and, as a consequence, its protective activity (Ciccarelli, unpublished observations).
In conclusion, this study shows that early administration of high dose AIT -082 is neuroprotective, not only reducing tissue damage but also improving locomotor recovery. The effects of AIT -082 are as good or better than the effects of high dose MPSS. Moreover, given either orally or intraperitoneally, AIT -082 has no appreciable side effect, and can cross the blood-brain-barrier (21) . Although numerous pharmacologic therapies have been evaluated in the treatment of SCI, none have met with significant success (63) . MPSS has become the 'standard' of clinical treatment for acute spinal cord injury. However, there are several studies reassessing MPSS in a more controlled manner, because of its side effects (64) . Therefore, our data confirm that AIT-082 has therapeutic potential for the human spinal cord injury.
However, AIT-082 and MPSS used together abolish each other's beneficial effects indicating that the two drugs should not be used simultaneously to treat acute spinal cord injury.
